FDA Jeopardizes the Lives of Lung Transplant Recipients and in the Process Severely Increases the Cost to Develop New Immunosuppression
American Journal of Transplantation - United Kingdom
doi 10.1111/ajt.15215
Full Text
Open PDFAbstract
Available in full text
Date
January 10, 2019
Authors
Publisher
Wiley